This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
5 Low Price-to-Book Stocks to Buy in a Volatile Market
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding
by Zacks Equity Research
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding
5 Dirt-Cheap PEG Stocks That Value Investors Love
by Zacks Equity Research
For investors looking to escape value traps, it is vital to determine where the stock is headed in the next 12 to 24 months.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Are Investors Undervaluing DaVita HealthCare (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is DaVita Inc. (DVA) a Great Stock for Value Investors?
by Zacks Equity Research
Is DaVita Inc. (DVA) a great pick from the value investor's perspective right now? Read on to know more.
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak
by Sweta Jaiswal
With the hurricane season at the peak, we bring three safe picks for investors.
DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand
by Zacks Equity Research
DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.
Here's Why You Should Hold On to DaVita (DVA) Stock Now
by Zacks Equity Research
Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.
Kidney Care Demand Shoots Up in US: 3 Stocks Likely to Gain
by Sreyoshi Mukherjee
As the U.S. dialysis industry has been garnering huge profits for decades, some dialysis stocks are worth a look.
DaVita HealthCare (DVA) Down 10.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DaVita Healthcare Partners' New Facility Now in Los Angeles
by Zacks Equity Research
DaVita's (DVA) incessant efforts to upgrade services, global expansion initiatives and active acquisitions are impressive.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q2.
DaVita HealthCare (DVA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 8.25% and 0.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Revenue, Membership Growth Aid Cigna (CI) Q2 Earnings?
by Zacks Equity Research
Cigna (CI) Q2 earnings is likely to gain from strong growth at its segments.
Will a Decline in Membership Mar Aetna's (AET) Q2 Earnings?
by Zacks Equity Research
Aetna (AET) Q2 earnings to suffer from lower membership and revenues partly offset by a lower tax rate.
Medical Stock Q2 Earnings Due on Aug 1: ESRX, DVA & HUM
by Zacks Equity Research
Solid R&D prospects likely to drive the healthcare industry in Q2 earnings.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Baxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.
Can Kidney Care Business Drive DaVita's (DVA) Q2 Earnings?
by Zacks Equity Research
DaVita's (DVA) flagship Kidney Care business likely to drive Q2 results; solid international presence encourages.
Here's Why You Should Invest in DaVIta (DVA) Stock Right Now
by Zacks Equity Research
Strong fundamentals and solid international presence make DaVita (DVA) a lucrative pick.
DVA vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. USPH: Which Stock Is the Better Value Option?
Outpatient & Home Healthcare Stock Outlook: Prospects Bright
by Zacks Equity Research
The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.
Varian Medical (VAR) Q3 Earnings: Surprise in Store?
by Zacks Equity Research
Solid prospects in the Oncology segment is likely to boost Varian Medical's (VAR) top-line performance in the third quarter of fiscal 2018.
Will Core Distribution Unit Aid McKesson (MCK) Q1 Earnings?
by Zacks Equity Research
Strong prospects in the Distribution Solutions segment is likely to boost McKesson's (MCK) top-line performance in the fiscal first quarter.